Rep. Lisa C. McClain Buys Cytokinetics, Incorporated (NASDAQ:CYTK) Shares

Representative Lisa C. McClain (R-Michigan) recently bought shares of Cytokinetics, Incorporated (NASDAQ:CYTK). In a filing disclosed on August 13th, the Representative disclosed that they had bought between $1,001 and $15,000 in Cytokinetics stock on June 11th. The trade occurred in the Representative’s “CHARLES SCHWAB BROKERAGE ACCOUNT 924” account.

Representative Lisa C. McClain also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Autoliv (NYSE:ALV) on 8/4/2025.
• Sold $1,001 – $15,000 in shares of Amazon.com (NASDAQ:AMZN) on 8/4/2025.
• Sold $1,001 – $15,000 in shares of Applied Materials (NASDAQ:AMAT) on 8/4/2025.
• Sold $1,001 – $15,000 in shares of Arthur J. Gallagher & Co. (NYSE:AJG) on 8/4/2025.
• Sold $1,001 – $15,000 in shares of SAP (NYSE:SAP) on 7/22/2025.
• Purchased $1,001 – $15,000 in shares of XPO (NYSE:XPO) on 7/22/2025.
• Purchased $1,001 – $15,000 in shares of Lithia Motors (NYSE:LAD) on 7/22/2025.
• Sold $1,001 – $15,000 in shares of Sanofi (NASDAQ:SNY) on 7/22/2025.
• Sold $1,001 – $15,000 in shares of Waters (NYSE:WAT) on 7/22/2025.
• Purchased $1,001 – $15,000 in shares of Group 1 Automotive (NYSE:GPI) on 7/22/2025.

Cytokinetics Trading Up 0.8%

Shares of CYTK opened at $38.34 on Friday. Cytokinetics, Incorporated has a 12-month low of $29.31 and a 12-month high of $59.39. The firm has a 50-day moving average price of $35.76 and a 200 day moving average price of $37.86. The firm has a market capitalization of $4.59 billion, a P/E ratio of -7.52 and a beta of 0.64.

Cytokinetics (NASDAQ:CYTK) last announced its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported ($1.12) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.34) by $0.22. The firm had revenue of $66.77 million during the quarter, compared to analysts’ expectations of $1.95 million. During the same period in the prior year, the company posted ($1.31) EPS. The company’s revenue for the quarter was up 26727.3% compared to the same quarter last year. Equities research analysts predict that Cytokinetics, Incorporated will post -5.24 earnings per share for the current fiscal year.

Insider Activity

In related news, EVP Andrew Callos sold 8,659 shares of the business’s stock in a transaction dated Thursday, June 5th. The shares were sold at an average price of $32.04, for a total value of $277,434.36. Following the completion of the transaction, the executive vice president owned 52,028 shares of the company’s stock, valued at approximately $1,666,977.12. The trade was a 14.27% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Edward M. Md Kaye sold 3,636 shares of Cytokinetics stock in a transaction dated Thursday, June 5th. The shares were sold at an average price of $32.10, for a total value of $116,715.60. Following the completion of the sale, the director owned 29,658 shares of the company’s stock, valued at $952,021.80. This trade represents a 10.92% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 40,295 shares of company stock worth $1,384,010. Company insiders own 2.70% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have commented on CYTK. JPMorgan Chase & Co. decreased their target price on shares of Cytokinetics from $71.00 to $53.00 and set an “overweight” rating on the stock in a research report on Monday, June 9th. Cantor Fitzgerald raised shares of Cytokinetics to a “strong-buy” rating in a research report on Tuesday, May 13th. Raymond James Financial initiated coverage on shares of Cytokinetics in a research report on Wednesday, July 30th. They issued a “market perform” rating on the stock. UBS Group reduced their price target on shares of Cytokinetics from $47.00 to $41.00 and set a “neutral” rating on the stock in a research report on Friday, May 2nd. Finally, Royal Bank Of Canada reduced their target price on shares of Cytokinetics from $82.00 to $80.00 and set an “outperform” rating on the stock in a report on Wednesday, May 7th. Two investment analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $71.58.

Hedge Funds Weigh In On Cytokinetics

Institutional investors have recently bought and sold shares of the company. LPL Financial LLC raised its position in Cytokinetics by 6.6% during the 4th quarter. LPL Financial LLC now owns 13,988 shares of the biopharmaceutical company’s stock worth $658,000 after buying an additional 870 shares during the last quarter. Bank of Montreal Can raised its stake in shares of Cytokinetics by 9.3% during the 4th quarter. Bank of Montreal Can now owns 15,136 shares of the biopharmaceutical company’s stock worth $712,000 after buying an additional 1,285 shares during the last quarter. Advisory Services Network LLC acquired a new position in Cytokinetics in the 4th quarter valued at about $270,000. Raymond James Financial Inc. acquired a new position in Cytokinetics in the 4th quarter valued at about $254,000. Finally, Capital Fund Management S.A. raised its stake in Cytokinetics by 13.9% in the 4th quarter. Capital Fund Management S.A. now owns 40,446 shares of the biopharmaceutical company’s stock valued at $1,903,000 after purchasing an additional 4,924 shares during the last quarter.

About Representative McClain

Lisa McClain (Republican Party) is a member of the U.S. House, representing Michigan’s 9th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027.

McClain (Republican Party) is running for re-election to the U.S. House to represent Michigan’s 9th Congressional District. She declared candidacy for the 2026 election.

Lisa McClain lives in Romeo, Michigan. McClain earned a bachelor’s degree in business administration from Northwood University. Her career experience includes founding and working as the president of North End Support Team.

Cytokinetics Company Profile

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.